INO Therapeutics LLC

INO Therapeutics LLC, a division of Medtronic Inc. and a foreign-owned manufacturer of pharmaceutical preparations, operates as a federal prime contractor supplying inhaled nitric oxide therapeutic gases, INOMAX delivery systems, and related respiratory therapy services to the Department of Veterans Affairs and Defense Health Agency across 29 federal customer agencies. The vendor competes full-and-open with no set-aside designations across all awards.

INO Therapeutics delivers specialized inhaled nitric oxide therapy products and services for neonatal, pediatric, and adult critical care patient populations at VA medical centers and military treatment facilities nationwide. Representative work includes a $557.7 thousand delivery order from VISN 6 (VA Central Virginia Healthcare System) for nitric oxide gas service (ultimate completion December 31, 2027), a $413.9 thousand delivery order from VISN 15 for INOMAX inhaled nitric oxide with delivery system (ultimate completion July 6, 2029), and a $512.9 thousand delivery order from the Defense Health Agency for inhaled nitric oxide therapeutic gases and respiratory therapy services at Portsmouth, Virginia (ultimate completion September 30, 2028). The portfolio spans 585 prime awards with a combined potential value of $101.5 million, of which $35.1 million is obligated; 51% of awards are concentrated among five customer agencies led by VISN 12 (33 awards, $58 million combined potential value), the Army Medical Command (62 awards, $11.3 million), and the Navy Bureau of Medicine and Surgery (127 awards, $5.6 million).

INO Therapeutics holds three active blanket purchase agreements serving as parent vehicles. The largest is a VISN 2 BPA (awarded October 1, 2022, ceiling $789.4 thousand through September 30, 2027) for INOMAX nitric oxide gas cylinder delivery services, which has generated 338 task orders; a second VISN 2 BPA (June 1, 2023, ceiling $2.3 thousand through May 31, 2027) for nitrous oxide gas inotherapy supplies; and a Defense Health Agency BPA (March 20, 2025, ceiling $404.2 thousand through March 19, 2030) for inhaled nitric oxide therapeutic gas. The Pharmaceuticals and Drugs GSA Schedule (FSS-61-IB) is the primary procurement vehicle, carrying 337 task orders worth $36.4 million combined potential value. Awards are categorized primarily under Pharmaceutical Preparation Manufacturing (477 awards) and Medical and Surgical Instruments, Equipment, and Supplies (202 awards by PSC code).

Awards per year have remained consistent over the last five years (ranging 8 to 15 per year), with 20 awards (combined potential value $2.7 million) reaching ultimate completion in the next twenty-four months and facing recompete. SCI-reported federal service invoicing totaled $150 thousand across FY2023–FY2024, reflecting minimal service-contract activity; government-paid hourly rates on SCI-reportable contracts ranged from $41.84/hr at the 10th percentile to a median of $46.62/hr, with specialized labor pricing reaching $268.78/hr at the 90th percentile. The vendor operates 100% as a prime contractor with no subcontract engagement; SCI data indicates roughly 0.9 FTEs in FY2023 and 0.3 FTEs in FY2024 on reportable service contracts, representing a subset of federal work and excluding goods-based revenue that dominates the award portfolio.